Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Neuron23 Inc. currently has 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 4 actions are distributed across 4 distinct examiners, meaning that every pending matter is being handled by a different individual. This level of examiner diversity is matched by the 4 distinct art units involved in the company's prosecution. The busiest examiner for the company is CHAO, ALLEN, who is responsible for 1 busiest examiner pending action. Because there are 4 pending office actions in total, this examiner handles 1 of the company's current pending workload.
The distribution of 4 pending office actions across 4 art units suggests that Neuron23 Inc. is pursuing a diverse range of technical claims within the Biotechnology & Pharmaceuticals sector. This variety provides the company with multiple channels of feedback from the patent office. The prosecution strategy must be tailored to the specific standards of 4 different art units and the individual preferences of 4 different examiners. This diversified examiner engagement reduces the impact of any 1 examiner's decision on the overall portfolio. Practitioners should coordinate their approach to ensure consistency across the 4 distinct examiners while respecting the unique technical standards of each art unit. The company's focus on Biotechnology & Pharmaceuticals is currently split between these 4 active prosecution paths.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| §102 only | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHAO, ALLEN | 1 | 60.0% | +0.0% |
| FERGUSON, JALISA HOLMES | 1 | 62.2% | +41.2% |
| JOHANNSEN, DIANA B | 1 | 53.2% | +42.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18032073 | METHODS OF TREATMENT AND DIAGNOSIS OF PARKINSON'S DISEASE ASSOCIATED WITH WILD-TYPE LRRK2 | JOHANNSEN, DIANA B | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18375063 | KINASE MODULATORS AND METHODS OF USE THEREOF | FERGUSON, JALISA HOLMES | 92d overdue |
| 18032073 | METHODS OF TREATMENT AND DIAGNOSIS OF PARKINSON'S DISEASE ASSOCIATED WITH WILD-TYPE LRRK2 | JOHANNSEN, DIANA B | — |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| 1626 | 1 |
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18512306 | LRRK2 INHIBITORS AND USES THEREOF | CHAO, ALLEN | 1622 | §102 | Non-Final OA | — | Pending | Nov 17, 2023 |
| 18375063 | KINASE MODULATORS AND METHODS OF USE THEREOF | FERGUSON, JALISA HOLMES | 1626 | §102 | Final Rejection | 92d overdue | Pending | Sep 29, 2023 |
| 18032073 | METHODS OF TREATMENT AND DIAGNOSIS OF PARKINSON'S DISEASE ASSOCIATED WITH WILD-TYPE LRRK2 | JOHANNSEN, DIANA B | 1682 | §101§102§112DP | Non-Final OA | — | Pending | Apr 14, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNeuron23 Inc. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Allen Chao has the most, with 1 of Neuron23 Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
